Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance

• Main Authors: Kristin eDickschen (Author), Stefan eWillmann (Author), Kirstin eThelen (Author), Jörg eLippert (Author), Georg eHempel (Author), Thomas eEissing (Author)
• Format: Book
• Published: Frontiers Media S.A., 2012-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tamoxifen is a first-line endocrine agent in the mechanism-based treatment of estrogen receptor positive (ER+) mammary carcinoma and applied to breast cancer patients all over the world. Endoxifen is a secondary and highly active metabolite of tamoxifen that is formed among others by the polymorphic...